MDH1/2-IN-1

MDH1/2-IN-1 is a MDH1/2 inhibitor (IC50: 1.07 nM and 1.06 nM respectively) . MDH1/2-IN-1 inhibits mitochondrial respiration and the HIF-1α pathway. MDH1/2-IN-1 demonstrates significant anti-tumor potential. MDH1/2-IN-1 provides a new direction for the development of drugs targeting cancer metabolism[1].

2143473-95-2

12352005

H302, H315, H319, H335

HIF/HIF Prolyl-Hydroxylase; Malate Dehydrogenase (MDH) ; Mitochondrial Metabolism

Metabolic Enzyme/Protease

Cancer-Kinase/protease

Cancer

99.53

DMSO : 100 mg/mL (ultrasonic)

O=C(C1=CC(NC(CCOC2=CC=C(C(C)(CC(C)(C)C)C)C=C2)=O)=CC=C1)OC

C25H33NO4

411.53

H302, H315, H319, H335

[1]Naik R, et al. Methyl 3- (3- (4- (2,4,4-Trimethylpentan-2-yl) phenoxy) -propanamido) benzoate as a Novel and Dual Malate Dehydrogenase (MDH) 1/2 Inhibitor Targeting Cancer Metabolism. J Med Chem. 2017 Oct 26;60 (20) :8631-8646.

Room Temperature

-20°C, 3 years; 4°C, 2 years (Powder)

http://file.medchemexpress.com/batch_PDF/HY-W613220/MDH1-2-IN-1-SDS-MedChemExpress.pdf

Reference compound1

No Development Reported